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Introduction
HIV-1 infection still remains a global epidemic with signifi-
cant morbidity and mortality. Although anti-retroviral therapy 
(ART) has extended the lives of HIV-1-infected individuals, it 
has several limitations including the need for life long therapy, 
high cost and side effects associated with the drugs.1 More-
over, the virus is not completely eradicated with this approach 
and rebounds rapidly upon interruption of ART.2,3 Hence, 
there has been interest in pursuing alternative strategies that 
are aimed at rendering cells intrinsically resistant to HIV-1.
Zinc finger nucleases (ZFNs) have been widely used for 
genome editing in various types of cells and living organ-
isms4–10 and is also a highly promising strategy for HIV-1 
therapy aimed at disrupting specific host genes important 
for virus replication,11–18 or to eliminate provirus in latently 
infected cells.19 There has been a renewed interest in CCR5 
disruption as a strategy for HIV-1 gene therapy because of 
the so-called “Berlin Patient”, who was completely cured of 
HIV-1 infection after receiving bone marrow stem cells trans-
planted from a donor homozygous for the Δ32 mutation (a 
32-bp deletion in the single coding exon of the gene) in the 
CCR5 gene which leads to blockade of HIV-1 entry via this 
co-receptor.20,21 Unlike conventional gene knockdown by 
RNAi, which requires the continued presence of the effector 
siRNA moiety for silencing to be maintained, transient ZFN 
expression results in permanent and heritable gene editing 
so that the CCR5-modified cells can confer long-term HIV-1 
resistance in patients. CCR5 disruption mediated by ZFNs 
has been tested in primary CD4+ T cells as well as in CD34+ 
stem cells.11–18 Reconstitution of NSG mice with activated 
CD4+ T cells transduced with adenovirus encoding CCR5-
ZFNs resulted in resistance to HIV-1 challenge.22 Promis-
ing new data have been reported from one of the ongoing 
clinical trials in which CCR5 gene modified autologous CD4+ 
T cells were used for adoptive therapy in HIV infected sub-
jects.23 The therapy was found to be safe and well tolerated. 
Moreover, increased levels of CD4+ T cells were seen follow-
ing treatment interruption, which attest to the feasibility of the 
approach. However, large-scale expansion of gene-edited 
cells for personal therapy is labor intensive and requires a 
specialized laboratory set up. Alternative simplified regimens 
may facilitate the dissemination of the therapeutic approach 
for large-scale clinical application.
Lentiviral vectors are among the most efficient gene deliv-
ery vehicles for primary cells, including T cells, making them 
attractive vectors for ZFN delivery for HIV-1 therapy. The 
third generation vectors currently used in gene therapy trials 
have undergone extensive modifications to ensure safety.24–26 
 Nevertheless, insertional mutagenesis could pose a potential 
risk for gene therapy with integrating lentiviral vectors.27,28 On 
the other hand, non-integrating lentivirus (NILV) generated 
by packaging vectors with a mutated integrase gene mini-
mizes vector integration into the host genome, which makes 
them ideal for gene editing applications, where only tran-
sient expression of the transgene is needed.29 Indeed, CCR5 
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CCR5 disruption by zinc finger nucleases (ZFNs) is a promising method for HIV-1 gene therapy. However, successful clinical 
translation of this strategy necessitates the development of a safe and effective method for delivery into relevant cells. We used non-
integrating lentivirus (NILV) for transient expression of ZFNs and pseudotyped the virus with HIV-envelope for targeted delivery to 
CD4+ T cells. Both activated and resting primary CD4+ T cells transduced with CCR5-ZFNs NILV showed resistance to HIV-1 infection 
in vitro. Furthermore, NILV transduced resting CD4+ T cells from HIV-1 seronegative individuals were resistant to HIV-1 challenge 
when reconstituted into NOD-scid IL2rγc null (NSG) mice. Likewise, endogenous virus replication was suppressed in NSG mice 
reconstituted with CCR5-ZFN–transduced resting CD4+ T cells from treatment naïve as well as ART-treated HIV-1 seropositive patients. 
Taken together, NILV pseudotyped with HIV envelope provides a simple and clinically viable strategy for HIV-1 gene therapy.
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disruption using a non-integrating lentiviral vector in human 
stem cells has been attempted in vitro,11 but the applicability 
of the approach for selective delivery to primary CD4+ T cells 
for inducing HIV-1 resistance remains untested.
In this work, we tested transduction efficiency and CCR5 
disruption frequency after ZFN delivery to cell lines and pri-
mary CD4+ T cells via a non-integrating lentiviral vector. In 
previous studies using adenoviral vector-based transduction, 
activated CD4+ T cells were gene-modified and expanded 
in vitro before transfusion.12,23 However, in addition to being 
time-consuming and expensive, extended culture after T-cell 
activation may result in an altered cell surface phenotype and 
exhaustion of the cells, which may have an impact on the effi-
cacy of gene therapy in the long-term.30–32 Although conven-
tional adenoviral and lentiviral vectors efficiently transduce 
a multitude of cell types, including primary cells, they are 
inefficient in transducing resting T cells.32,33 Here, we used 
NILV pseudotyped with HIV-1 envelope to enable transduc-
tion of unstimulated CD4+ T cells from healthy or HIV-infected 
donors. This allowed selective transduction of the cells within 
unfractionated PBMCs, which could then be infused into 
NSG mice (Hu/PBL model) without further in vitro manipula-
tion and then evaluated for reconstitution and resistance to 
HIV-1 infection. These efforts are anticipated to lead to the 
development of a simple approach for generating HIV-resis-
tant cells for cellular therapy in HIV-1 infected patients.
RESULTS
Construction and characterization of non-integrating 
CCR5-ZFN encoding lentivirus
Non-integrating lentivirus has been demonstrated to success-
fully infect various types of cell lines, as well as stem cells 
without integration of viral DNA into the cellular genome.29,34 
For nucleolytic activity, two arms of Zinc finger nucleases are 
designed to bind to 9–18 nucleotides on the left and right 
hand side of the targeted gene on the sense and antisense 
strands respectively. To improve the disruption efficiency, we 
expressed the ZFN pair targeting a specific site within the 
CCR5 gene in a single construct by connecting them via a 
FMDV 2A sequence (Supplementary Figure S1a, for the 
ZFN protein sequence see Supplementary  Figure S1c). The 
sequence was cloned into the lentiviral vector, pLVX-ZsGreen 
(a bicistronic IRES vector to allow simultaneous expression of 
ZFNs and ZsGreen from the same RNA transcript, enabling 
easy confirmation of ZFNs expression by monitoring ZsGreen 
expression) under the CMV promoter to produce a fusion 
protein containing both arms (Supplementary Figure S1b). 
However, this fusion protein is expected to be cleaved soon 
after translation, because of self-cleavage activity of the 2A 
sequence,35 yielding two functional units that simultaneously 
target their respective DNA binding sites. To derive the NILV, 
the ZFN vector was co-transfected with a packaging plasmid 
and an envelope (either VSV-G env or HIV-1 env) encoding 
plasmid into 293 T cells and the supernatants collected after 
48 hours of culture. In order to achieve transient ZFN expres-
sion, we used an intergrase-defective packaging plasmid, 
vTK939, to package the lentivirus. In vitro and in vivo studies 
have demonstrated that the resulting lentivirus shows much 
lower levels of illegitimate integration.36 We first tested the 
transduction efficiency of the VSV-G pseudotyped non-inte-
grating vector compared with the integrating lentiviral vector 
in HEK 293 T cells. The results show that 48 hours after lenti-
viral infection, ZsGreen expression was comparable between 
the two vectors (Supplementary Figure S1d). To evaluate 
whether NILV expression was more transient compared to 
conventional integrating LV, we transduced 293 T cells with 
both vectors at a multiplicity of infection (MOI) of 10 (20 ng 
of p24 for 1 × 105 cells) and then monitored the GFP expres-
sion over time. In the 10 day period of observation, the GFP 
fluorescence was progressively lost in NILV transduced cells, 
declining to baseline level by day 8 whereas the percentage of 
GFP-positive cells remained stable after transduction with the 
WT integrating vector (Supplementary Figure S2).
The MTS cell viability assay did not reveal any overt cyto-
toxic effects of NILV-mediated ZFN expression in 293T cells 
(Supplementary Figure S3). In silico genome-wide analysis 
with PROGNOS software for potential off target gene modi-
fication by the ZFN sequences used in this study (obtained 
from Sigma-Aldrich, St Louis, MO) did not reveal any off-
target sites when no mismatch was allowed but showed 32 
potential off-target sites when two mismatches per ZFN half-
site were allowed.37 However, deep sequencing data with 
K562 cells treated with the same ZFN pair by another group 
revealed no detectable off-target activity.38
We next evaluated the efficiency of CCR5 disruption after 
NILV-mediated ZFN delivery in 293T cells. CCR5 disruption 
was quantified by PCR amplification across the CCR5 locus, 
heating and re-annealing of PCR products, and digestion 
with T7 endonuclease, which is able to cleave mismatched 
dsDNA caused by non-homologous end joining (NHEJ).39 At 
an MOI of 30 (60 ng of p24 for 1 × 105 cells), the transduction 
efficiency was 63.8%, for HEK293T cells, with a correspond-
ing CCR5 disruption frequency of 60% (Figure 1a).
HIV envelope pseudotyped NILV can deliver ZFNs to 
resting and activated CD4+ T cells to efficiently disrupt 
the CCR5 gene
Findings from multiple studies indicate poor transduction 
of unstimulated but not stimulated CD4+ T cells with VSV-G 
pseudotyped lentiviral particles.32,40 As CXCR-4 tropic HIV 
envelope pseudotyping has been shown to allow efficient len-
tiviral transduction of quiescent CD4+ T cells,32 we used this 
approach for NILV-mediated delivery of ZFNs to HIV-1-sus-
ceptible resting and activated CD4+ T cells. We first tested 
whether the HIV envelope pseudotyped NILV could deliver 
ZFNs to CD4 expressing Jurkat cells. As shown in Figure 1b, 
at an MOI of 30 (60 ng of p24 for 1 × 105 cells), the transduc-
tion efficiency was 39.1% with a corresponding CCR5 disrup-
tion frequency of 34%.
We next compared NILV transduction in resting and acti-
vated primary T cells with conventional VSV-G or HIV env 
pseudotyped NILV, using ZsGreen to track expression. In 
agreement with previous data,32 we found equivalent ZsGreen 
expression with both HIV env and VSV-G in CD4+ T cells acti-
vated with phytohemagglutinin (PHA) prior to transduction. 
On the other hand, in unstimulated CD4+ T cells, there was 
negligible ZsGreen expression with VSV-G, whereas with 
HIV-env pseudotyped NILV the expression level was compa-
rable to that in activated T cells (Supplementary Figure S4).
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We also evaluated whether HIV env pseudotyping could 
be used for selective ZFN delivery to CD4+ T cells within a 
mixed PBMC population. PBMCs isolated from a normal 
donor were transduced with NILV at an MOI of 10 (20 ng of 
p24 for 1 × 105 cells) and after 48 hours of culture, ZsGreen 
expression on CD8, CD4, and CD19 gated cells was evalu-
ated by flow cytometry. As shown in Supplementary Figure 
S5, after transduction, ZsGreen was expressed only in CD4+ 
T cells and not in CD8+ T cells or in B cells (CD19+).
CCR5 editing efficiency was also compared between PHA 
activated and resting primary CD4+ T cells transduced with 
ZFN-expressing HIV-env pseudotyped NILV at an MOI of 
30. Resting cells were stimulated with PHA 4 hours after 
transduction. After 2 days of culture, the CCR5 disruption 
frequency was found to be 28% for prior activated and 22% 
for resting CD4+ T cells with a corresponding transduction 
efficiency of 44% and 38.1% respectively (Figure 1c–e).
In the previous experiment, the resting cells were activated 
following NILV transduction, so it was important to directly 
test whether ZFN-cleavage was activation dependent or 
could occur even in the absence of any stimulation. To test 
this, resting CD4+ T cells transduced with NILV at an MOI of 
15 (30 ng p24 for 1 × 105 cells) were cultured for 2 days with 
or without PHA activation and T7 endonuclease assay was 
performed with genomic DNA extracted from the cells. The 
results show that the CCR5 locus was successfully disrupted 
with an efficiency of 10% in unstimulated, compared with 
18% in CD4+ T cells that were activated 4 hours after trans-
duction (Figure 1f). The transduction efficiency assessed 
by ZsGreen expression was 13% and 24% with or without 
activation respectively (data not shown), so the proportion 
of ZFN cleavage in the transduced cells was similar in both 
cases (about 75% of the transduced population).
CCR5 disruption protects primary CD4+ T cells from 
HIV-1 infection in vitro
To investigate whether CCR5 disruption by CCR5-ZFNs 
NILV can suppress HIV-1 infection, primary CD4+ T cells 
Figure 1  ZFN-expressing NILV-mediated disruption of CCR5 gene in cell lines and primary human CD4+ T cells. (a) Transduction 
efficiency and CCR5 disruption efficiency of HEK 293 cells. HEK 293 cells were transduced with CCR/ZFNs NILV pseudotyped with VSV-G 
at an MOI of 30 and examined for ZsGreen expression by flow cytometry after 48 hours. The genomic DNA extracted from the transduced 
cells was tested for CCR5 disruption by T7 endonuclease assay using a Tris-Acetate PAGE gel. Empty vector (GFP only) was used as control. 
(b) Transduction efficiency and CCR5 disruption efficiency in Jurkat cells after ZFN delivery with HIV envelope pseudotyped NILV. (c) PHA-
activated CD4+ T cells were transduced with CCR5/ZFN NILV pseudotyped with HIV envelope at an MOI of 30 and ZsGreen-positive cells 
were enumerated by flow cytometry. (d) Resting CD4+ T cells were transduced as in c, and then activated with PHA 4 hours after transduction. 
For both activated and resting CD4+ T cells transduction assays, the empty NILV (without CCR5/ZFN) was used as control. (e) The frequency 
of CCR5 disruption in activated and resting CD4+ T cells (activated 4 hours after transduction) was assessed by T7 endonuclease assay. 
(f) The frequency of ZFN-mediated CCR5 disruption in resting CD4+ T cells with or without activation after transduction. Purified resting 
CD4+ T cells were transduced with NILV at an MOI of 15. The frequency of CCR5 disruption assessed by T7 nuclease assay is indicated 
as percentage of total population, calculated by the formula: 100 × [1 − (1 − fraction of cleavage)1/2]. Representative data from experiments 
performed at least three times are shown.
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were transduced with HIV-pseudotyped NILV at an MOI of 
30 (60 ng of p24 for 1 × 105 cells) and then challenged with 
CCR5 tropic HIV-1 isolate HIVBaL at an MOI of 0.1 (200 pg 
p24 for 1 × 105 cells). Activated cells were transduced with 
NILV and then challenged with HIV-1 48 hours after trans-
duction, whereas resting CD4+ T cells were first transduced 
with NILV, activated with PHA for 2 days and then subjected 
to viral challenge. Supernatants were collected from the cul-
tures on days 1, 4, 7, 10, and 14 for viral load determina-
tion by qRT-PCR. With mock and control vector transduction, 
the response pattern to HIV-1 challenge was very similar in 
both activated and resting CD4+ T cells in that the viral load 
peaked at day 7, and then dropped two- to fourfolds after 
day 14. We reason that this decrease in viral load is caused 
by the decreasing availability of CD4+ T cells for further de 
novo infection. By contrast, in both resting and activated 
CD4+ T cells transduced with CCR5-ZFNs, the viral load was 
substantially lower than either non-transduced or vector-
transduced CD4+ T cells on day 7, and became nearly unde-
tectable by 14 days after infection. These results suggest that 
CCR5 disruption protects against HIV-1 infection and thus 
provides survival advantage to the cells (Figure 2a,b).
CCR5 disruption in resting CD4+ T cells from a seronegative 
donor confers HIV-1 resistance in Hu/PBL mice
We used the Hu/PBL model to assess whether CCR5-ZFNs-
transduced resting CD4+ T cells can be reconstituted in 
humanized mice, and whether the gene modified cells are 
able to resist HIV-1 infection in vivo. CD4+ T cells isolated 
from a HIV-1 seronegative donor, were transduced with HIV-
pseudotyped NILV for 2 hours at an MOI of 10 (200 ng of p24 
per 2 × 106 cells) and injected into the animals (5 × 105 CD4+ 
cells/mouse) along with 0.5 million unmanipulated PBMCs 
to facilitate engraftment. Non-transduced and empty NILV 
vector-transduced cells were also similarly injected in sepa-
rate groups of mice as negative controls. All mice were chal-
lenged with 100 ng p24 of R5-tropic virus, HIVBaL 5 days after 
cell infusion. The CD4+ T cell profile (% CD3+CD4+) was mon-
itored on days 7, 21, 34, and 42 (Figure 3a). The transduc-
tion efficiencies for vector and CCR5-ZFNs NILV were 10.1% 
and 16.7% respectively (Figure 3b). On day 7 after infusion, 
similar levels of CD4 reconstitution (around 50–70%) were 
observed in all groups. However, by day 21 after challenge, 
the control LV-transduced and non-transduced groups exhib-
ited a dramatic decrease in CD3+CD4+ cells, compared to the 
CCR5-ZFN group, where five out of eight animals showed 
a significantly higher percentages of CD3+CD4+ cells. Fur-
thermore, the CD4+ T cell levels were maintained over time 
in CCR5-ZFN group as assessed on days 21, 34, and 42, 
whereas the levels consistently remained low in both non-
transduced group and vector-transduced groups (Figure 3c). 
We also investigated whether transfer of ZFN modified CD4+ 
T cells could control plasma viremia by determining the p24 
levels by ELISA in sera collected after sacrificing the animals 
7 weeks after challenge. The results revealed that HIV-1 was 
at a very low level in most of the animals in the ZFN group 
(around 10 pg/ml in four mice and 50 pg/ml in one mouse), 
whereas the control groups showed a high viral load, ranging 
from 100–900 pg/ml (Figure 3d). The three animals in the 
ZFN group that failed to maintain their CD4 counts showed 
viral loads similar to the control mice. The result of p24 
ELISA was also corroborated by analysis of HIV-1 cDNA late 
reverse transcripts (LRTs) by qRT-PCR.41 Even here, in the 
CCR5-ZFN transduced group, the viral loads were very low 
in the same five protected animals (1,000–2,500 copies/ml), 
whereas both non-transduced and vector transduced groups 
presented a significantly higher viral load (average around 
10,000 copies/ml) (Figure 3e). Overall, these results suggest 
that transient ZFN expression in resting CD4+ T cells using 
HIV envelope pseudotyped NILV can generate HIV-1-resis-
tant cells that efficiently engraft and expand in humanized 
mice.
The increase in the proportion of CD4+ T cells over time 
in the CCR5-ZFN group suggests that CCR5 disruption pro-
vides survival advantage to the gene modified relative to the 
non-transduced CD4+ T cells, which became infected and 
died. To confirm CCR5 disruption in this population, genomic 
DNA extracted from purified CD4+ T cells was subjected to T7 
endonuclease assay. For many of the unprotected mice, the 
T7 endonuclease assay could not be carried out because of 
a paucity of CD4+ T cells after HIV-1 challenge. By contrast, 
the CCR5 ZFN-protected showed an average disruption fre-
quency of 71.8%, confirming the enrichment of protected 
cells (Figure 3f).
Figure 2 CCR5-ZFN-expressing NILV transduced activated and 
resting CD4+ T cells resist HIV infection in vitro. (a) activated or 
(b) resting CD4+ T cells were challenged with HIVBAL 48 hours after 
transduction and the supernatants collected at different time points 
were tested by LRT qRT-PCR to determine the viral titers. PBMC and 
empty NILV were used as controls. All the samples for qRT-PCR were 
in triplicates and plotted as average copy numbers. One way analysis 
of variance was used to compare the differences between groups at 
different time points. Significance levels are shown in the figures as 
*P < 0.05; **P < 0.01; and ***P < 0.001.
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Suppression of endogenous virus in Hu/PBL mice 
engrafted with CCR5 modified resting CD4+ T cells from 
HIV-1-seropositive subjects
Infusion of autologous CCR5 gene modified CD4+ T cells 
is being tried as a potential therapy for HIV-1 infection. 
Towards this end, we tested the protective efficacy of ZFN-
mediated CCR5 disruption in Hu/PBL mice reconstituted 
with PBMCs from HIV-1+ donors. As HIV pseudotyped NILV 
is expected to selectively target CD4+ T cells, we directly 
transduced 3 × 106 PBMCs from the patients in the absence 
of CD4+ T-cell purification. PBMCs transduced at an MOI of 
10 (300 ng of p24 for 3 × 106 PBMCs) without prior activation 
were infused into NSG mice. The CD4+ T-cell levels were 
monitored over time and sera collected at the time of sacri-
fice were used for viral load analysis.
We first tested the strategy with PBMCs from two treat-
ment-naïve HIV-1+ subjects with high viral loads (for patient 
information see Supplementary Table S1). We used only four 
mice for each group (mock and ZFN transduced) because of 
limitation of the number of cells available. PBMCs from only 
one of the two subjects showed successful engraftment in 
NSG mice, with three out of four animals in both control and 
test groups showing adequate human cell reconstitution. The 
results showed that the CD4 count was maintained in the 
CCR5 ZFN-transduced group (CD3+CD4+ levels between 
49–57%), whereas in the mock-transduced group, the CD4+ 
T cells dropped from a mean of 59% on day 7 to a mean of 
20% on day 42 (Figure 4a). Protection was also assessed 
by measuring the viral load by p24 ELISA in sera collected 
on day 49 after transplantation. The viral load was very much 
reduced in the ZFN group (average 25 pg/ml blood, with 
undetectable virus in one animal) compared with the mock 
treated group (averaging 360 pg/ml) (Figure 4b). Consistent 
with the p24 ELISA results, a qRT-PCR assay also revealed 
that the average viral load was around 1,500 copies/ml blood 
in CCR5 ZFN group, whereas in the mock treated group it 
was about fivefold higher (Figure 4c).
Next, we used the same Hu/PBL model to test HIV-1 resis-
tance mediated by CCR5 disruption in resting PBMCs from 2 
HIV-1+ subjects on ART, whose viral loads were undetectable 
Figure 3 Reconstitution with ZFN-treated CD4+ T cells from a normal donor protects Hu-PBL mice from HIV challenge. (a) Schematic 
of study design. (b) NILV transduction efficiency in resting CD4 T cells used for infusion into Hu-PBL mice. (c) CD4 T-cell counts at different 
time points in HIV infected Hu-PBL mice infused with 0.5 × 106 CD4 cells treated with CCR5-ZFN- (8 mice), empty vector- (6 mice, 1 mouse 
died on day 21), or left untreated (6 mice, 1 mouse died on day 28) along with 0.5 × 106 unfractionated PBMCs. One-way ANOVA was used 
to compare the difference between these three groups. ns = P > 0.05; *P < 0.05; **P < 0.01; and ***P < 0.001. (d,e) Viral load measured 
(d) by p24 ELISA or (e) by qRT-PCR using sera collected on Day 49. Multiple T test was used to test the significances between groups. 
ns = P > 0.05; *P < 0.05. (f) T7 endonuclease assay with human CD4+ T cells isolated from spleen on day 49 from 5 ZFN-treated and 1 vector 
control-treated mice. Lane 1: Vector control; Lanes 2–6: ZFN group. The frequency of CCR5 gene disruption is indicated as percentage, 
calculated by the formula: 100 × [1 − (1 − fraction of cleavage)1/2].
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(Subject 24, S24) or at very low level (Subject 30, S30). In 
both cases, good human cell engraftment was observed in 
all mice (Figure 4d,e). The CD4 levels on day 7 were slightly 
higher for subject S30 (30% for the vector-treated and 23% 
for ZFN-treated group) than for subject S24 (24% for the vec-
tor-treated and 16% for ZFN-treated group), which is consis-
tent with the CD4+ T-cell counts in the input PBMCs (40% in 
S30 and 27% in S24). Although the CD4+ T-cell counts were 
slightly higher in the control group compared with the CCR5/
ZFNs group on day 7, CD4+ T cells in this group gradually 
declined for both subjects (dropping from an average of 24% 
on day 7 to 12.7% on day 35 for S30 and from 23% to 3% for 
S24) (Figure 4,e). By contrast, in the CCR5/ZFN group, the 
CD4+ T-cell levels increased with time (from ~23% to ~45% 
for S30, and from 16% to 50% for S24).
As the viral load was below detection by p24 ELISA in 
all groups (data not shown), we used the more sensitive 
qRT-PCR assay to evaluate plasma viremia. The results 
showed that the virus remained below the limit of detection 
(<60 copies/ml) in the sera of 6/7 mice (for S30) and 5/7 mice 
(for S24) in the CCR5-ZFN group, whereas for both subjects, 
a significantly higher viral load was detected in all the control 
mice (Figure 4f,g).
Taken together, these results demonstrate that direct trans-
duction of PBMCs from HIV-1 seropositive subjects with HIV-
1-pseudotyped NILV is a feasible approach for CCR5 gene 
editing; and that after infusion into Hu/PBL mice, the gene 
modified cells are protected from HIV-1 infection.
Discussion
Here, we used a non-integrating lentiviral system for transient 
expression of ZFNs to edit the CCR5 gene in primary CD4+ 
Figure 4 Direct ZFN transduction of whole PBMCs from treated or untreated seropositive individuals confers protection from 
endogenous virus in Hu-PBL mice. Whole PBMCs (3 x 106) from indicated subjects were mock-transduced or transduced with HIV env 
pseudotyped NILV and injected iv into NSG mice. CD4 T-cell counts over time (a) viral loads measured by (b) p24 ELISA, and (c) qRT-PCR 
in sera collected on day 49 in Hu-PBL mice infused with PBMCs from an ART negative HIV-1+ individual. Multiple T test was used to compare 
the differences between Vector or ZFN treated groups (three mice each group), significance values are shown in the figures. *P < 0.05, **P < 
0.01. (d–g) CD4 T-cell counts over time (d,e) and viral load measured by qPCR in sera collected on day 35 (f,g) in Hu-PBL mice infused with 
CD4 T cells from two ART treated HIV positive individuals. Multiple t-test was used to compare the differences between Vector (n = 4 for S24 
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T cells. More importantly, pseudotyping NILV with HIV enve-
lope allowed targeting of resting CD4 T cells, obviating the 
need for CD4+ T-cell isolation from PBMCs or prior activa-
tion. Using the Hu/PBL mouse model, we also showed that 
the gene modified resting CD4+ T cells from normal, as well 
as HIV-1+ donors, could engraft and provide protection from 
HIV-1 infection in vivo.
Recently, multiple studies have demonstrated the efficacy 
of ZFN-mediated CCR5 disruption as a therapeutic strategy 
to block HIV-1 infection.11–13,17,22 Adenoviral vector has been 
the preferred vehicle for ZFN delivery because of its ability 
to transduce hard to transfect primary cells.42 Despite a simi-
lar advantage, conventional lentiviral vectors have not been 
utilized because of their propensity to integrate into the host 
genome, which poses the obvious risk of insertional muta-
genesis. In addition, long-term expression of ZFN from an 
integrated transgene can also increase the risks of off tar-
get effects.43–45 Tracking of ZsGreen expression revealed 
that NILV expression in cultured cells decreased to a nearly 
undetectable level by day 8, which is in agreement with pub-
lished data showing that NILV expression through cell divi-
sion reaches baseline levels by day 10.29 These properties 
of NILV make it well suited for transient ZFN expression to 
confer stable CCR5 gene modification and thereby induce 
HIV-1 resistance in susceptible cells.
Integrase defective vectors are known to induce only tran-
sient accumulation of episomal DNA in the nucleus as they 
retain a very weak integration capacity compared with WT 
vectors.46,47 NILVs lacks the integrase protein that facilitates 
integration, but background integrations due to illegitimate 
IN-independent insertions still occurs in transduced cells, 
the reported rate of which has varied considerably.48 With the 
D64E mutant used in this study, the residual integration was 
demonstrated to be ~0.2% in NILV-transduced 293T cells.36 
Suwanmanee et al. have reported a 35-fold reduction in inte-
gration frequencies in liver tissue when the same D64E vec-
tor used in this study was injected in vivo to correct factor IX 
deficiency in a mouse model of hemophilia.49 Thus, although 
very low, some residual illegitimate integrations do occur with 
NILV, which poses a definite safety concern for clinical use 
of NILV. Recent studies have shown that the frequency of 
such residual integration can be reduced to minimal levels by 
using a PPT deleted vector.36 Another potential risk for use of 
NILV for HIV-1 therapy is the possibility that in HIV-1 infected 
cells NILVs could be complemented in trans by an active inte-
grase of similar specificity. As suggested by Lombardo et al. 
incorporating cis-acting mutations in the integrase attach-
ment sites of the vector may prevent such a rescue.11
The ZFNs employed for CCR5 gene targeting in this study 
were obtained from a commercial source (Sigma-Aldrich) 
and differ in sequence from the one from Sangamo Biosci-
ences that has been used in multiple studies for CCR5 gene 
editing in hematopoietic stem cells and primary T cells.12,13,18 
In silico genome-wide analysis of the sequences targeted by 
the ZFN pair used in this study did not reveal any off-target 
sites. Although allowing two mismatches per ZFN half-site for 
in silico analysis identifies 32 potential off target sites, deep 
sequencing data published by Badia et al. found no off tar-
get effects in human K562 cells transfected with the same 
ZFN pair.38 However, the recent demonstration that NILV can 
be captured at sites of double stranded breaks induced by 
ZFNs by nonhomologous end joining suggests that such ille-
gitimate integrations could also contribute to off target toxic-
ity.50,51 Thus, for actual clinical use, the genome wide impact 
of NILV-mediated ZFN delivery in primary T cells has to be 
understood. The potential for insertional mutagenesis is 
somewhat mitigated by studies showing that mature CD4+ 
T cells are relatively resistant to oncogenic transformation in 
vivo even after transduction with integrating retroviral vector 
expressing potent T-cell oncogenes.52
Conventionally, VSV-G is used for pseudotyping lentivi-
ruses because of its broad tropism for many different cell 
types. However, cells in the G0 stage of the cell cycle, such 
as resting CD4+ T cells are highly recalcitrant to transduction 
with VSV-G pseudotyped lentivirus. On the other hand, unlike 
VSV-G, CXCR4-tropic HIV envelope has been shown to 
mediate fusion of lentiviral particles in both unstimulated and 
stimulated CD4+ T cells.32 Our study also shows that lentivi-
rus packaged with X4-tropic envelope from LAI can efficiently 
deliver ZFNs for CCR5 disruption into resting CD4+ T cells. 
This makes it possible to selectively target HIV-1 susceptible 
CD4+ T cells within unfractionated PBMC population. Fur-
thermore, as ex vivo transduction is the only external manip-
ulation required, after ZFN modification, the PBMCs can be 
immediately infused back into the patient, which would sim-
plify ZFN-based therapy for wider clinical application.
CCR5 disruption has been the goal in most studies evalu-
ating ZFNs for HIV-1 therapy. This is because the vast major-
ity of newly transmitted HIV-1 strains use the co-receptor and 
CCR5 tropic viruses predominate during the early stages of 
infection.53–55 Nevertheless, over time, there is a significant 
increase in quasispecies that utilize CXCR4 as an alterna-
tive co-receptor for infection.55–59 Thus, in addition to CCR5, 
CXCR4 disruption may also be needed, particularly for the 
treatment of chronically infected patients.
Although a majority of animals transplanted with CCR5 
ZFNs modified CD4 T cells were protected from HIV-1 chal-
lenge, we also observed that some animals (3 out of 8 ani-
mals receiving PBMCs from a normal donor and 2 out of 14 
animals receiving patient PBMCs) failed to show protection. 
Although the reason for this is not clear, another study also 
found that a fraction of animals treated with CCR5 ZFN-mod-
ified T cells remained unprotected.12 As only a small number 
of xenoreactive cells are expected to expand after infusion of 
resting CD4+ T cells, it is possible that paucity of gene modi-
fied cells within this fraction in some of the animals could 
explain the lack of protection. Thus, increasing the infusion 
size may be necessary to show complete antiviral efficacy in 
humanized mice.
Taken together, our study demonstrates that NILV can 
serve as a potentially useful alternative vector for ZFN-
mediated CCR5 alteration. HIV envelope pseudotyping of 
NILV allows unfractionated PBMCs from HIV-1 patients to 
be directly transduced ex vivo and reinfused back into the 
patients without extensive ex vivo manipulation. As no T-cell 
activation or large-scale expansion of gene modified cells are 
involved, the impact on immune homeostasis is likely to be 
minimal. The simplicity of the delivery approach used here is 
likely to broaden the scope of ZFNs-mediated CCR5 disrup-
tion for HIV-1 gene therapy.
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Cells and cell culture. HEK 293T cells and TZM-bl cells were 
cultured in complete DMEM medium (Dulbecco’s modi-
fied Eagle’s medium supplemented with 10% fetal bovine 
serum (FBS), and penicillin-streptomycin-glutamine (PSG, 
100 units/ml penicillin, 100 μg/ml streptomycin, and 2 mmol/l 
L-glutamine). Jurkat cells were cultured in complete RPMI 
medium (RPMI 1640 medium supplemented with 10% 
FBS and PSG). Human Peripheral blood mononuclear cells 
(PBMCs) were purified from normal human donor blood by 
Ficoll density gradient centrifugation. Primary CD4+ T cells 
were purified from either healthy donors or patients’ PBMCs 
by two rounds of negative selection using the EasySep 
Human CD4+ T-cell enrichment kit (Stemcell Technologies, 
Vancouver, BC, Canada) according to the manufacturer’s 
instructions.
Lentiviral vector. A CCR5-ZFN plasmid pair encoding the 
left and right ZFN arms was purchased from Sigma-Aldrich 
(St Louis, MO). Lentiviral vector pLVX-ZsGreen was pur-
chased from Clontech Laboratory (Mountain View, CA). 
The following primer pairs were used to amplify ZFN1 and 
ZFN2 fragments from CCR5-ZFNs plasmids: zfn1 forward: 
cgctctgaattcgccaccatggactacaaagaccatgac (which includes 
a kozak sequence and the start codon) and zfn1 reverse: 
gcccctcgagagatctgaagttgatctcgc; zfn2 forward: gcccctc-
gagggatccggagccacgaacttctctctgttaaagcaagcaggagacgtg-
gaagaaaaccccggtcctatgagatctgactacaaagac (which contains 
a 2A sequence from foot-and-mouth disease virus) and 
zfn2 reverse: ccgacatctagattatcagaagttgatctcgccg. After 
PCR amplification of zfn fragments, the zfn1 fragment was 
digested with EcoR I/Xho I and zfn2 with Xho I/Xba I. pLVX-
ZsGreen vector was digested with EcoR I/Xba I and the three 
digested fragments were ligated together at a molar ratio of 
1:1:1 and transformed into E. coli DH5α. The resulting recom-
binant plasmid (pLVX-ZFN1-2A-ZFN2) which co-expresses 
both ZFN arms was used to transfect 293T cells to generate 
lentivirus.
Generation and titration of lentivirus. 1 × 107 293 T cells were 
co-transfected with 20 μg of vector plasmid (pLVX-ZFN1-
2A-ZFN2, or pLVX as control), 16 μg of packaging plasmid 
and 10 μg of envelope plasmid using Polyethylenimine (PEI, 
Polysciences, Warrington, PA).60 For integrating lentivi-
rus, pHR’8.9ΔVPR was used as packaging plasmid (which 
expresses functional integrase)61; while vTK939 (which 
expresses D64E-mutant integrase) was used in a similar 
manner as when making non-integrating lentivirus.36 The 
plasmids pCMV-VSV-G or pHIV LAI (generously provided by 
Dr Una O’Doherty at the University of Pennsylvania) were 
used for pseudotyping the lentiviruse with VSV-G and HIV-1 
envelopes respectively. After 30 minutes of transfection, 
DMEM supplemented with 10% FBS and PSG was added 
and the cells were incubated at 37 °C under 5% CO2. Two 
days later, the supernatants were collected, filtered (low 
binding filter, PVDF membrane, Millipore) and concentrated 
by ultracentrifugation at 25,000g at 4 °C using an SW 40 Ti 
rotor for 2.5 hours and the lentivirus pellets were dissolved 
in PBS. To determine the viral titers, 293 T or TZM-bl cells 
were transduced with VSV-G or HIV-1 pseudotyped lentivirus 
respectively. Briefly, 1 × 105 cells were spin-transduced with 
serially diluted lentivirus preparations in serum free DMEM in 
the presence of 7 μg/ml polybrene (Sigma-Aldrich) at 1,200 g 
for 2 hours, and then incubated at 37 °C for another 2 hours. 
After changing medium to complete DMEM, the transduced 
cells were incubated at 37 °C for 48 hours. The cells were 
then fixed with 1% formaldehyde. The transduction efficiency 
was quantified by evaluating the infected cells for GFP 
expression by flow cytometry.
T7 endonuclease assay. Genomic DNA was extracted 
using the GenElute Mammalian Genomic DNA miniprep kit 
(Sigma-Aldrich) according to the manufacturer’s instructions. 
The frequency of gene modification by NHEJ was evaluated 
as described previously.16 Briefly, the purified genomic DNA 
was used as a template to amplify a fragment of the CCR5 
gene using the specific primers (CCR5 forward: 5′-TTTT-
GTGGGCAACATGCTGGTCATCCT-3′ and CCR5 reverse: 
5′-TGTAGGGAGCCCAGAAGAGA-3′), to yield a 346 bp 
amplicon. To amplify the CCR5 gene fragment in CD4+ T 
cells from humanized mice the primer pairs were: CCR5 for-
ward: 5′-GGTCATCCTCATCCTGAT-3′ and CCR5 reverse: 
5′-TGTAGGGAGCCCAGAAGAGA-3′) which results in a 
605 bp amplicon. The PCR products were gel purified, dena-
tured and re-annealed to form heteroduplex DNA, followed 
by treatment with T7 endonuclease. Since T7 endonuclease 
is mismatch-sensitive, the insertions and deletions caused by 
NHEJ could be detected by running a 7% Tris-Acetate PAGE 
gel and quantitated by densitometry using Quantity One 
4.6.6 software. The disruption frequency was defined as 100 
× [1-(1-fraction cleaved)1/2], wherein the fraction cleaved is 
the density sum of the cleaved bands divided by the density 
sum of the cleaved bands and un-cleaved band.
Viral load determination. HIV-1 viral loads in cell culture or in 
the sera were determined by HIV-1 cDNA Late Reverse Tran-
scripts (LRTs) qRT-PCR and/or p24 ELISA. LRTs PCR was 
performed as described elsewhere26 but with a small modifi-
cation. Briefly, for cell culture supernatants, the supernatants 
were treated with 10% Triton-100, then directly used for qRT-
PCR. For mice sera, RNAs were isolated according to the 
manufacturer’s instructions (QIAamp viral RNA mini kit, Qia-
gen, Germantown, MD), and used as PCR templates. The 
PCR mixtures were formulated according to the manufac-
turer’s instructions (Taqman Fast Virus 1-Step Master Mix kit, 
Life Technologies, Grand Island, NY). The primers (Sigma-
Aldrich) were as follows: MH531 (5′ TGTGTGCCCGTCT-
GTTGTGT 3′), MH532 (5′ GAGTCCTGCGTCGAGAGAGC 
3′), and fluorescent probe LRT-P (5′ FAM-CAGTGGCGCCC-
GAACAGGGA-TAMRA 3′). The PCR mixtures were incu-
bated at 95 °C for 5 minutes, followed by 40 cycles of 95 
°C for 15 seconds and 60 °C for 1 minute. A sample quanti-
tated by the 4th generation Roche Cobas Ampliprep/TaqMan 
method at the Laboratory of Clinical and Biological studies, 
Miller School of Medicine, University of Miami was used as 
standard. A standard curve generated using dilutions of this 
standard to calculate the absolute copy numbers of copies. 
The lower limit of detection of the assay was determined to be 
50 copies/ml. The Alliance HIV-1 ELISA kit from PerkinElmer 
www.moleculartherapy.org/mtna
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(Waltham, MA) was used to perform p24 ELISA according to 
the manufacturer’s instructions.
Lentivirus transduction and HIV-1 challenge in vitro. 293 T 
cells, Jurkat cells and primary CD4+ T cells were used for len-
tiviral transduction. CD4+ T cells were purified from PBMCs of 
HIV-1-seronegative donors by two rounds of negative selec-
tion. CD4+ T cells were transduced either directly (resting) or 
after activation with PHA (1 μg/ml) in the presence of 50 U/
ml rIL-2 for 2 days. In brief, 1 × 105 cells were spin-transduced 
with VSV-G or HIV-pseudotyped lentivirus (ZFN or control 
virus) at indicated multiplicity of infection (MOI). Resting CD4 
T cells were activated with PHA following transduction for 2 
days before HIV-1 challenge. Cells were then infected with 
the CCR5 tropic strain HIVBAL (stocked in our laboratory) at 
an MOI of 0.1 (200 pg of p24 for 1 × 105 cells). Supernatants 
collected at various time points were assayed for viral titers.
Testing HIV-1 resistance in Hu-PBL mice. All work with ani-
mals was approved by the Institutional Review Board of the 
Texas Tech University Health Sciences Center.
NOD.cg PrkdcscidIL2rgtm/Wjl/Sz (NSG) mice were purchased 
from the Jackson Laboratory (Bar Harbor, ME). Hu-PBL mice 
were essentially generated as described.62 PBMCs from 
HIV-1 seronegative or seropositive individuals on or off ART 
were used. Freshly prepared PBMCs or negatively isolated 
CD4+ T cells (2 × 105) were transduced with HIV-pseudotyped 
lentivirus as described earlier. The cells were injected intra-
venously (iv) in a volume of 0.2 ml PBS into irradiated (180 
rads) 4–6 week-old mice. Transduced CD4+ T cells were 
infused after mixing with 5 × 105 untreated PBMCs (as a 
source of antigen presenting cells to promote engraftment). 
Cell engraftment was tested 5 days after transplantation 
by flow cytometric analysis of PBMCs stained with human 
CD45, CD3, CD4, and CD8 antibodies. Animals receiving 
PBMCs from HIV-1-seronegative donors were infected with 
100 ng p24 of HIVBAL by intraperitoneal (ip) route 5–7 days 
after human cell transfer. Blood samples from the animals 
were periodically assayed for viral load and CD4+ T cell 
changes. After 7 weeks blood and spleen from euthanized 
animals were harvested for final analysis.
Statistical analysis. Statistical analyses were performed with 
GraphPad Prism version 6. Data between groups were com-
pared using one-way analysis of variance with Bonferroni 
correction, or multiple t-tests. P < 0.05 was considered sig-
nificant and P < 0.01 was considered extremely significant.
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